Preparative scale synthesis of the biaryl core of anacetrapib via a ruthenium-catalyzed direct arylation reaction: Unexpected effect of solvent impurity on the arylation reaction

Journal of Organic Chemistry

Volumn 76, Issue 5, 2011, Pages 1436-1439

  Ouellet, Stéphane G ^a   Roy, Amélie ^a   Molinaro, Carmela ^a   Angelaud, Rémy ^a   Marcoux, Jean François ^b   OShea, Paul D ^a   Davies, Ian W ^b  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLATION REACTIONS; ARYLATIONS; CHROMATOGRAPHY-FREE SYNTHESIS; COCATALYST;

AROMATIC COMPOUNDS; CARBOXYLATION; CATALYSIS; RUTHENIUM;

SYNTHESIS (CHEMICAL);

ANACETRAPIB; RUTHENIUM;

ARTICLE; ARYLATION; CATALYST; CHEMICAL REACTION; CHROMATOGRAPHY; DRUG IMPURITY; DRUG SYNTHESIS;

CATALYSIS; MOLECULAR STRUCTURE; OXAZOLIDINONES; RUTHENIUM; SOLVENTS; STEREOISOMERISM;

EID: 79952128821     PISSN: 00223263     EISSN: 15206904     Source Type: Journal    
DOI: 10.1021/jo1018574     Document Type: Article

References (57)

1. For general references on Pd-catalyzed cross-coupling reactions, see: Metal-Catalyzed Cross-Coupling Reactions, 2nd ed.; Meijere, A. d. and Diederich, F., Eds.; Wiley-VCH: Weinheim, Germany, 2004.
2. Ackermann, L.; Vicente, R.; Kapdi, A. R. Angew. Chem., Int. Ed. 2009, 48, 9792
3. Bellina, F.; Rossi, R. Tetrahedron 2009, 65, 10269
4. Kulkarni, A. A.; Daugulis, O. Synthesis 2009, 24, 4087
5. Chen, X.; Engle, K.; Wang, D.-H.; Yu, J.-Q. Angew. Chem., Int. Ed. 2009, 48, 5094
6. McGlacken, G. P.; Bateman, L. M. Chem. Soc. Rev. 2009, 38, 2447
7. Kakiuchi, F.; Kochi, T. Synthesis 2008, 3013
8. Li, B.-J.; Yang, S.-D.; Shi, Z.-J. Synlett 2008, 949
9. Campeau, L.-C.; Fagnou, K. Chem. Soc. Rev. 2007, 36, 1058
10. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; ODonnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y. Circulation 2009, 119, 480
11. Zhong, S.; Sharp, D. S.; Grove, J. S.; Bruce, C.; Yano, K.; Curb, J. D.; Tall, A. R. J. Clin. Invest. 1997, 12, 2917
12. Bruce, C.; Sharp, D. S.; Tall, A. R. J. Lipid Res. 1998, 39, 1071
13. Vergeer, M.; Kastelein, J. J. P. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5, 302
14. Pfizer entered a phase III clinical study with Torcetrapib. This study was halted in 2006 because of elevated blood pressure. Initial studies revealed that Anacetrapib could elevate HDL with no effect on blood pressure.
15. ONeill, E.; Sparrow, C. P.; Chen, Y.; Eveland, S.; Frantz-Wattley, B.; Milot, D.; Sinclair, P. J.; Ali, A.; Lu, Z.; Smith, C. J.; Taylor, G.; Thompson, C. F.; Anderson, M. S.; Cumiskey, A.; Rosa, R.; Strain, J.; Peterson, L. B. J. Clin. Lipidol. 2007, 1, 367
16. Ali, A.; Napolitano, J. M.; Deng, Q.; Lu, Z.; Sinclair, P. J.; Taylor, G. E.; Thompson, C. F.; Quraishi, N.; Smith, C. J.; Hunt, J. A.; Dowst, A. A.; Chen, Y.-H.; Li, H. PCT Int. Appl. WO 2006014413, 2006.
17. Ali, A.; Napolitano, J. M.; Deng, Q.; Lu, Z.; Sinclair, P. J.; Taylor, G. E.; Thompson, C. F.; Quraishi, N.; Smith, C. J.; Hunt, J. A. PCT Int. Appl. WO 2006014357, 2007.
18. Ali, A.; Sinclair, P. J. PCT Int. Appl. WO 2007041494, 2007.
19. Ali, A.; Sinclair, P. J.; Taylor, G. E. PCT Int. Appl. WO 2007081570, 2007.
20. Ali, A.; Lu, Z.; Sinclair, P. J.; Chen, Y.-H.; Smith, C. J.; Li, H. PCT Int. Appl. WO 2007079186, 2007.
21. For examples of Ni-contaminated Cr(II)-catalyzed coupling reactions, see: Takai, K.; Tagashira, M.; Kuroda, T.; Oshima, K.; Utimoto, K.; Nozaki, H. J. Am. Chem. Soc. 1986, 108, 6048
22. Jin, H.; Uenishi, J.-I.; Christ, W. J.; Kishi, Y. J. Am. Chem. Soc. 1986, 108, 5644
23. For examples of copper-contaminated Fe-catalyzed cross-coupling reactions, see: Buchwald, S. L.; Bolm, C. Angew. Chem., Int. Ed. 2009, 48, 5586
24. Angelaud, R.; OShea, P.; Ouellet, S.; Roy, A. PCT Int. Appl. WO 2007136672, 2007.
25. For the preparation of the oxazolidinone, see: Miller, R. A. PCT Int. Appl. WO 2008/082567, 2008.
26. Ouellet, S. G.; Bernardi, A.; Angelaud, R.; OShea, P. D. Tetrahedron Lett. 2009, 50, 3776
27. The bis-addition product formed could easily be removed by fractional distillation to provide a highly enriched mixture of isomer 6.
28. After fractional distillation (90 °C, 3-5 Torr), the isomeric ratio was 18.5:1 (6: 7) with 0.48% 1-bromo-2,4-dimethoxybenzene. These impurities were rejected during the crystallization of acylated product 8.
29. 4 were tried without success.
30. Oi, S.; Aizawa, E.; Ogino, Y.; Inoue, Y. J. Org. Chem. 2005, 70, 3113
31. On a 1 mmol scale, >90% conversion was observed, and the reaction profile was slightly cleaner when NMP was used.
32. These studies were conducted on a 5-10 g scale.
33. γ-Butyrolactone is a common impurity found in NMP.
34. Other additives such as TFA, pivalic acid, and 4-methylbenzoic acid were tested and were found to have a favorable effect on the reaction efficiency.
35. For a recent review on metal-catalyzed direct arylation, see: Ackermann, L.; Vivente, R. In Modern Arylation Methods; Ackermann, L., Ed.; Wiley-VCH: Weinheim, Germany, 2009; pp 311 -399. For selected examples of reactions developed in NMP, see
36. Özdemir, I.; Demir, S.; Çetinkaya, B.; Gourlaouen, C.; Maseras, F.; Bruneau, C.; Dixneuf, P. H. J. Am. Chem. Soc. 2008, 130, 1156
37. Ackermann, L. Org. Lett. 2005, 7, 2123
38. Oi, S.; Sakai, K.; Inoue, Y. Org. Lett. 2005, 7, 4009
39. Ackermann, L.; Novák, P.; Vivente, R.; Hofmann, N. Angew. Chem., Int. Ed. 2009, 48, 6045
40. Ackermann, L.; Althammer, A.; Born, R. Angew. Chem., Int. Ed. 2006, 45, 2619
41. Lafrance, M.; Fagnou, K. J. Am. Chem. Soc. 2006, 128, 16496
42. Lafrance, M.; Gorelsky, S. I.; Fagnou, K. J. Am. Chem. Soc. 2007, 129, 14570
43. Campo, M. A.; Larock, R. C. J. Am. Chem. Soc. 2002, 124, 14326
44. Campo, M. A.; Huang, Q.; Yao, T.; Tian, Q.; Larock, R. C. J. Am. Chem. Soc. 2003, 125, 11506
45. Arockiam, P.; Poirier, V.; Fischmeister, C.; Bruneau, C.; Dixneuf, P. H. Green Chem. 2009, 11, 1871
46. Požgan, F.; Dixneuf, P. H. Adv. Synth. Catal. 2009, 351, 1737
47. Ackermann, L.; Mulzer, M. Org. Lett. 2008, 10, 5043
48. Ackermann, L.; Vivente, R.; Althammer, A. Org. Lett. 2008, 10, 2299
49. Ackermann, L.; Novák, P. Org. Lett. 2009, 11, 4966
50. Ackermann, L.; Novák, P.; Vicente, R.; Pirovano, V.; Potukuchi, H. K. Synthesis 2010, 2245
51. Ackermann, L.; Vicente, R. Org. Lett. 2009, 11, 4922
52. Ackermann, L.; Vicente, R.; Potukuchi, H. K.; Pirovano, V. Org. Lett. 2010, 12, 5032
53. Jensen, M. S.; Hoerrner, R. S.; Li, W.; Nelson, P. D.; Javadi, G. J.; Dormer, P. G.; Cai, D.; Larsen, R. D. J. Org. Chem. 2005, 70, 6034
54. Gauthier, D. J., Jr.; Limanto, J.; Devine, P. N.; Desmond, R. A.; Szumigala, R. H., Jr.; Foster, B. S.; Volante, R. P. J. Org. Chem. 2005, 70, 5938
55. Cameron, M.; Foster, S. B.; Lynch, J. L.; Shi, Y.-J.; Dolling, U.-H. Org. Process Res. Dev. 2006, 10, 398
56. Bernardi, A.; Ouellet, S. G.; Angelaud, R.; OShea, P. D. Tetrahedron Lett. 2008, 49, 6707
57. For completion of the synthesis of Anacetrapib, see: Miller, R. A.; Cote, A. S. PCT Int. Appl. WO 2007/005572, 2007.